

Claus RÃ¶del

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11458176/publications.pdf>

Version: 2024-02-01

181
papers

21,500
citations

22153

59
h-index

9345

143
g-index

210
all docs

210
docs citations

210
times ranked

14683
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2022, 8, e215445.	7.1	127
2	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2022, 167, 300-307.	0.6	5
3	Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. <i>Cancer Cell</i> , 2022, 40, 168-184.e13.	16.8	117
4	Neoadjuvant Chemoradiotherapy for Oral Cavity Cancer: Predictive Factors for Response and Interim Analysis of the Prospective INVERT-Trial. <i>Frontiers in Oncology</i> , 2022, 12, 817692.	2.8	4
5	Do We Have Enough Evidence to Propose a Preferred Total Neoadjuvant Therapy Sequence for Patients With Locally Advanced Rectal Cancer?â€”Reply. <i>JAMA Oncology</i> , 2022, , .	7.1	0
6	Bayesian network structure for predicting local tumor recurrence in rectal cancer patients treated with neoadjuvant chemoradiation followed by surgery. <i>Physics and Imaging in Radiation Oncology</i> , 2022, 22, 1-7.	2.9	4
7	ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group. <i>Clinical and Translational Radiation Oncology</i> , 2022, 34, 99-106.	1.7	7
8	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2022, 171, 91-100.	0.6	4
9	Advances in nanotechnology-based platforms for survivin-targeted drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 733-754.	5.0	10
10	Are We There Yet? The Value of Deep Learning in a Multicenter Setting for Response Prediction of Locally Advanced Rectal Cancer to Neoadjuvant Chemoradiotherapy. <i>Diagnostics</i> , 2022, 12, 1601.	2.6	3
11	Emerging Treatment Paradigms in Localized Rectal Cancer. <i>Practical Radiation Oncology</i> , 2021, 11, 26-29.	2.1	0
12	Tumor Suppressor Protein p53 and Inhibitor of Apoptosis Proteins in Colorectal Cancerâ€”A Promising Signaling Network for Therapeutic Interventions. <i>Cancers</i> , 2021, 13, 624.	3.7	17
13	Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial. <i>European Journal of Cancer</i> , 2021, 144, 281-290.	2.8	6
14	International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 805-816.	27.6	93
15	A Spatial and Functional Interaction of a Heterotetramer Survivinâ€™DNA-PKcs Complex in DNA Damage Response. <i>Cancer Research</i> , 2021, 81, 2304-2317.	0.9	8
16	Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial. <i>Radiotherapy and Oncology</i> , 2021, 164, 223-231.	0.6	8
17	The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper. <i>Radiotherapy and Oncology</i> , 2020, 142, 6-16.	0.6	12
18	Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer â€” study protocol of a prospective, single arm, multicenter phase II trial (RACE IT). <i>BMC Cancer</i> , 2020, 20, 8.	2.6	19

#	ARTICLE	IF	CITATIONS
19	Association of Sex With Toxic Effects, Treatment Adherence, and Oncologic Outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trials of Rectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 294.	7.1	12
20	The long-term influence of hospital and surgeon volume on local control and survival in the randomized German Rectal Cancer Trial CAO/ARO/AIO-94. <i>Surgical Oncology</i> , 2020, 35, 200-205.	1.6	2
21	Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer. <i>Oral Oncology</i> , 2020, 111, 104931.	1.5	16
22	Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial. <i>Clinical Cancer Research</i> , 2020, 26, 5368-5379.	7.0	42
23	RADIANCE – Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. <i>Clinical and Translational Radiation Oncology</i> , 2020, 23, 43-49.	1.7	16
24	Fractionation-Dependent Radiosensitization by Molecular Targeting of Nek1. <i>Cells</i> , 2020, 9, 1235.	4.1	5
25	Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 1416.	7.1	19
26	Outcome measures in multimodal rectal cancer trials. <i>Lancet Oncology</i> , The, 2020, 21, e252-e264.	10.7	56
27	Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 801-810.	2.8	10
28	The Diagnosis and Treatment of Patients with Bladder Carcinoma. <i>Deutsches A&#x0308;rztblatt International</i> , 2020, 118, .	0.9	4
29	Reply to A. Abdalla et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 3562-3563.	1.6	1
30	Association of Polo-Like Kinase 3 and PhosphoT273 Caspase 8 Levels With Disease-Related Outcomes Among Cervical Squamous Cell Carcinoma Patients Treated With Chemoradiation and Brachytherapy. <i>Frontiers in Oncology</i> , 2019, 9, 742.	2.8	5
31	Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. <i>Journal of Clinical Oncology</i> , 2019, 37, 3212-3222.	1.6	333
32	Organ Preservation in Rectal Cancer: The Patients' Perspective. <i>Frontiers in Oncology</i> , 2019, 9, 318.	2.8	44
33	Characterization of the tumor immune micromilieu and its interference with outcome after concurrent chemoradiation in patients with oropharyngeal carcinomas. <i>Oncolmunology</i> , 2019, 8, 1614858.	4.6	24
34	Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. <i>International Journal of Cancer</i> , 2019, 145, 2282-2291.	5.1	21
35	Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 20.	2.8	18
36	C-Reactive Protein-to-Albumin Ratio as Prognostic Marker for Anal Squamous Cell Carcinoma Treated With Chemoradiotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 1200.	2.8	19

#	ARTICLE	IF	CITATIONS
37	A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection. <i>Clinical Cancer Research</i> , 2019, 25, 1505-1516.	7.0	67
38	Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 126-137.	7.4	12
39	Anal squamous cell carcinoma – State of the art management and future perspectives. <i>Cancer Treatment Reviews</i> , 2018, 65, 11-21.	7.7	37
40	When Should Preoperative Radiochemotherapy Be Performed?. , 2018, , 159-163.		0
41	Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 214-221.	0.6	7
42	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. <i>Radiotherapy and Oncology</i> , 2018, 127, 27-35.	0.6	17
43	Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. <i>Clinical Cancer Research</i> , 2018, 24, 1364-1374.	7.0	45
44	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 125-131.	0.6	24
45	Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2018, 142, 1911-1925.	5.1	50
46	Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials. <i>Radiotherapy and Oncology</i> , 2018, 128, 557-563.	0.6	7
47	Cost analysis of a wait-and-see strategy after radiochemotherapy in distal rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 985-990.	2.0	5
48	Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2485.	4.1	25
49	Radiation Therapy in Rectal Cancer. , 2018, , 1-21.		0
50	Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer. <i>JAMA Surgery</i> , 2018, 153, e181607.	4.3	77
51	Radiation Therapy in Bladder Cancer. , 2018, , 1-12.		0
52	Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 305-314.	2.0	7
53	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2017, 141, 594-603.	5.1	91
54	The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 221-230.	7.4	23

#	ARTICLE	IF	CITATIONS
55	Human papilloma virus load and PD-1/PD-L1, CD8 ⁺ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy. <i>OncImmunity</i> , 2017, 6, e1288331.	4.6	79
56	A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling. <i>Scientific Reports</i> , 2017, 7, 13206.	3.3	163
57	SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2017, 5, 28-36.	1.7	16
58	Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	105
59	Complete response after chemoradiotherapy for rectal cancer: what is the reasonable approach?. <i>Innovative Surgical Sciences</i> , 2017, 3, 47-53.	0.7	0
60	Basics of Radiation Biology When Treating Hyperproliferative Benign Diseases. <i>Frontiers in Immunology</i> , 2017, 8, 519.	4.8	26
61	Peripheral Leukocytosis Is Inversely Correlated with Intratumoral CD8+ T-Cell Infiltration and Associated with Worse Outcome after Chemoradiotherapy in Anal Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1225.	4.8	29
62	Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8. <i>Cell Research</i> , 2016, 26, 914-934.	12.0	35
63	Stage-Dependent Frequency of Lymph Node Metastases in Patients With Rectal Carcinoma After Preoperative Chemoradiation: Results from the CAO/ARO/AIO-94 Trial and From a Comparative Prospective Evaluation With Extensive Pathological Workup. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 377-385.	1.3	23
64	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2016, 121, 364-373.	0.6	130
65	Targeted agents in GI radiotherapy: Clinical efficacy and side effects. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 537-549.	2.4	5
66	Rectal cancer: Neoadjuvant chemoradiotherapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 629-639.	2.4	49
67	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(+) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. <i>Clinical Cancer Research</i> , 2016, 22, 2639-2649.	7.0	127
68	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). <i>International Journal of Cancer</i> , 2016, 138, 171-181.	5.1	184
69	Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy. <i>Oncotarget</i> , 2016, 7, 53339-53349.	1.8	12
70	A 4-miRNA signature predicts the therapeutic outcome of glioblastoma. <i>Oncotarget</i> , 2016, 7, 45764-45775.	1.8	35
71	The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis. <i>Radiation Oncology</i> , 2015, 10, 198.	2.7	27
72	Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTX) – From Preclinical Studies to a Clinical Phase II Trial. <i>Frontiers in Immunology</i> , 2015, 6, 162.	4.8	87

#	ARTICLE	IF	CITATIONS
73	The role of recent nanotechnology in enhancing the efficacy of radiation therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1856, 130-143.	7.4	46
74	Study of the anti-inflammatory effects of low-dose radiation. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 742-749.	2.0	55
75	Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2015, 16, 979-989.	10.7	577
76	Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2015, 114, 302-309.	0.6	49
77	Downstage migration after neoadjuvant chemoradiotherapy for rectal cancer: The reverse of the Will Rogers phenomenon?. <i>Cancer</i> , 2015, 121, 1724-1727.	4.1	23
78	Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients. <i>International Journal of Cancer</i> , 2015, 137, 212-220.	5.1	94
79	Human papillomavirus DNA load and p16 ^{INK4a} expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. <i>International Journal of Cancer</i> , 2015, 136, 278-288.	5.1	75
80	Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer. <i>Oncolmmunology</i> , 2014, 3, e27403.	4.6	61
81	Organ-Sparing Multimodality Treatment for Muscle-Invasive Bladder Cancer: Can We Continue to Ignore the Evidence?. <i>Journal of Clinical Oncology</i> , 2014, 32, 3787-3788.	1.6	18
82	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2014, 113, 317-323.	0.6	141
83	Tumor Regression Grading After Preoperative Chemoradiotherapy for Locally Advanced Rectal Carcinoma Revisited: Updated Results of the CAO/ARO/AIO-94 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1554-1562.	1.6	351
84	Preoperative therapy for rectal cancer: Short-course radiation vs. long-course chemoradiation. <i>Seminars in Colon and Rectal Surgery</i> , 2014, 25, 19-21.	0.3	4
85	EURECCA consensus conference highlights about rectal cancer clinical management: The radiation oncologist's expert review. <i>Radiotherapy and Oncology</i> , 2014, 110, 195-198.	0.6	61
86	EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum. <i>European Journal of Cancer</i> , 2014, 50, 1.e1-1.e34.	2.8	349
87	A non-linear detection of phospho-histone H2AX in EA.hy926 endothelial cells following low-dose X-irradiation is modulated by reactive oxygen species. <i>Radiation Oncology</i> , 2014, 9, 80.	2.7	21
88	Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival. <i>Cancer</i> , 2013, 119, 26-35.	4.1	46
89	Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. <i>Radiation Oncology</i> , 2013, 8, 90.	2.7	36
90	Female sex is an independent risk factor for reduced overall survival in bladder cancer patients treated by transurethral resection and radio- or radiochemotherapy. <i>World Journal of Urology</i> , 2013, 31, 1023-1028.	2.2	26

#	ARTICLE	IF	CITATIONS
91	Preoperative Chemoradiation Therapy With Capecitabine/Oxaliplatin and Cetuximab in Rectal Cancer: Long-Term Results of a Prospective Phase 1/2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 992-999.	0.8	19
92	Double targeting of Survivin and XIAP radiosensitizes 3D grown human colorectal tumor cells and decreases migration. <i>Radiotherapy and Oncology</i> , 2013, 108, 32-39.	0.6	29
93	EURECCA colorectal: Multidisciplinary Mission statement on better care for patients with colon and rectal cancer in Europe. <i>European Journal of Cancer</i> , 2013, 49, 2784-2790.	2.8	76
94	Targeting by cmHsp70.1-antibody coated and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells. <i>Journal of Controlled Release</i> , 2013, 172, 201-206.	9.9	49
95	Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: Long-term results of the German CAO/ARO/AIO-94 phase III trial. <i>Radiotherapy and Oncology</i> , 2013, 108, 48-54.	0.6	25
96	Lymph Node Metastases in Rectal Cancer After Preoperative Radiochemotherapy. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1283-1289.	3.7	30
97	Frequency of HER-2 Positivity in Rectal Cancer and Prognosis. <i>American Journal of Surgical Pathology</i> , 2013, 37, 522-531.	3.7	64
98	Immunomodulatory Properties and Molecular Effects in Inflammatory Diseases of Low-Dose X-Irradiation. <i>Frontiers in Oncology</i> , 2012, 2, 120.	2.8	97
99	Chemoradiation superior in muscle-invasive bladder cancer. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 374-375.	27.6	6
100	Rectal cancer. <i>Current Opinion in Oncology</i> , 2012, 24, 441-447.	2.4	35
101	Short-Course Radiation Versus Long-Course Chemoradiation for Rectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1223-1231.	4.9	10
102	What Prognostic Clinical Factors Must Be Considered Before Treatment?. , 2012, , 21-26.		1
103	Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 679-687.	10.7	585
104	A radiosensitizing effect of artesunate in glioblastoma cells is associated with a diminished expression of the inhibitor of apoptosis protein survivin. <i>Radiotherapy and Oncology</i> , 2012, 103, 394-401.	0.6	46
105	Expression of TIP60 (tata€interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment€specific outcome of localised invasive bladder cancer. <i>BJU International</i> , 2012, 110, E1228-36.	2.5	92
106	Neoadjuvant Short- or Long-Term Radio(chemo)therapy for Rectal Cancer: How and Who Should Be Treated?. <i>Digestive Diseases</i> , 2012, 30, 102-108.	1.9	23
107	Survivin-miRNA-loaded nanoparticles as auxiliary tools for radiation therapy: preparation, characterisation, drug release, cytotoxicity and therapeutic effect on colorectal cancer cells. <i>Journal of Microencapsulation</i> , 2012, 29, 685-694.	2.8	21
108	High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy. <i>Radiation Oncology</i> , 2012, 7, 88.	2.7	13

#	ARTICLE	IF	CITATIONS
109	Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years. <i>Journal of Clinical Oncology</i> , 2012, 30, 1926-1933.	1.6	1,673
110	Failure of Downregulation of Survivin Following Neoadjuvant Radiochemotherapy in Rectal Cancer Is Associated with Distant Metastases and Shortened Survival. <i>Clinical Cancer Research</i> , 2011, 17, 1623-1631.	7.0	37
111	EGF61 Polymorphism Predicts Complete Pathologic Response to Cetuximab-Based Chemoradiation Independent of KRAS Status in Locally Advanced Rectal Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 5161-5169.	7.0	42
112	Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: Are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy?. <i>Radiotherapy and Oncology</i> , 2011, 98, 99-104.	0.6	62
113	Survivin inhibition and DNA double-strand break repair: A molecular mechanism to overcome radioresistance in glioblastoma. <i>Radiotherapy and Oncology</i> , 2011, 101, 51-58.	0.6	70
114	Nomograms for Predicting Local Recurrence, Distant Metastases, and Overall Survival for Patients With Locally Advanced Rectal Cancer on the Basis of European Randomized Clinical Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 3163-3172.	1.6	439
115	Radiotherapy and "new" drugs-new side effects?. <i>Radiation Oncology</i> , 2011, 6, 177.	2.7	53
116	Biomarkers for Cetuximab-Based Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3469-3477.	7.0	51
117	15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. <i>Anticancer Research</i> , 2011, 31, 985-90.	1.1	75
118	Radiation Therapy for Early Stages of Morbus Ledderhose. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 24-29.	2.0	56
119	Combined-Modality Treatment for Anal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 361-366.	2.0	24
120	Induction Chemotherapy before Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 658-664.	2.0	28
121	Regional lymph node metastasis and locoregional recurrence of rectal carcinoma in the era of TNM surgery. Implications for treatment decisions. <i>International Journal of Colorectal Disease</i> , 2010, 25, 359-368.	2.2	51
122	Concurrent Chemoradiotherapy With 5-Fluorouracil and Mitomycin C for Invasive Anal Carcinoma in Human Immunodeficiency Virus-Positive Patients Receiving Highly Active Antiretroviral Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1425-1432.	0.8	72
123	Preoperative Radiotherapy of Advanced Rectal Cancer With Capecitabine and Oxaliplatin With or Without Cetuximab: A Pooled Analysis of Three Prospective Phase I-II Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 472-478.	0.8	53
124	Radiation-Induced Survivin Nuclear Accumulation is Linked to DNA Damage Repair. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 226-234.	0.8	53
125	Preoperative chemoradiotherapy for rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 129-130.	27.6	14
126	Alternatives to surgery after failure of instillation therapy. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 307-308.	27.6	1

#	ARTICLE	IF	CITATIONS
127	Discontinuous induction of X-linked inhibitor of apoptosis in EA.hy.926 endothelial cells is linked to NF- κ B activation and mediates the anti-inflammatory properties of low-dose ionising-radiation. <i>Radiotherapy and Oncology</i> , 2010, 97, 346-351.	0.6	44
128	Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. <i>Radiotherapy and Oncology</i> , 2010, 97, 382-386.	0.6	77
129	Polo-Like Kinase 1 as Predictive Marker and Therapeutic Target for Radiotherapy in Rectal Cancer. <i>American Journal of Pathology</i> , 2010, 177, 918-929.	3.8	58
130	Radiation Therapy: Adjuvant vs. Neoadjuvant Therapy. , 2010, , 223-234.		0
131	Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. <i>Lancet Oncology</i> , The, 2010, 11, 835-844.	10.7	1,532
132	Colorectal Carcinoma. <i>Deutsches A&#x0308;rztblatt International</i> , 2009, 106, 843-8.	0.9	27
133	Molecular targeted treatment and radiation therapy for rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 371-378.	2.0	50
134	Caveolin-1 as a Prognostic Marker for Local Control After Preoperative Chemoradiation Therapy in Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 846-852.	0.8	15
135	Survivin Expression as a Predictive Marker for Local Control in Patients With High-Risk T1 Bladder Cancer Treated With Transurethral Resection and Radiochemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1455-1460.	0.8	30
136	The abdominoperineal resection itself is associated with an adverse outcome: The European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer. <i>European Journal of Cancer</i> , 2009, 45, 1175-1183.	2.8	171
137	Harnblasenkarzinom. , 2009, , 395-476.		1
138	Activator protein 1 shows a biphasic induction and transcriptional activity after low dose X-irradiation in EA.hy.926 endothelial cells. <i>Autoimmunity</i> , 2009, 42, 343-345.	2.6	26
139	Differences Between Clinical Trial Participants and Patients in a Population-Based Registry. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 425-437.	1.3	37
140	Treatment Options for High-Risk T1 Bladder Cancer. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 443-449.	2.0	10
141	Phase I-II Trial of Cetuximab, Capecitabine, Oxaliplatin, and Radiotherapy as Preoperative Treatment in Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1081-1086.	0.8	138
142	Management of Superficial Recurrences in an Irradiated Bladder After Combined-Modality Organ-Preserving Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1502-1506.	0.8	49
143	Prognostic Value of Pathologic Complete Response After Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Long-Term Analysis of 566 ypCR Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 99-107.	0.8	396
144	Survivin Antisense Oligonucleotides Effectively Radiosensitize Colorectal Cancer Cells in Both Tissue Culture and Murine Xenograft Models. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 247-255.	0.8	96

#	ARTICLE	IF	CITATIONS
145	Evidence and research in rectal cancer. <i>Radiotherapy and Oncology</i> , 2008, 87, 449-474.	0.6	92
146	Molecular Signature for Lymphatic Metastasis in Colorectal Carcinomas. <i>Annals of Surgery</i> , 2008, 247, 803-810.	4.2	32
147	Nuclear export is essential for the tumor-promoting activity of survivin. <i>FASEB Journal</i> , 2007, 21, 207-216.	0.5	116
148	Radiotherapy for Bladder Cancer. <i>Urology</i> , 2007, 69, 80-92.	1.0	68
149	Multicenter Phase II Trial of Chemoradiation With Oxaliplatin for Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 26, 110-117.	1.6	204
150	Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: Results of study CAO/ARO/AIO-94. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1008-1019.	0.8	69
151	Radiochemotherapy With Cisplatin and 5-Fluorouracil After Transurethral Surgery in Patients With Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1072-1080.	0.8	88
152	Pretreatment Proliferation and Local Control in Bladder Cancer after Radiotherapy with or without Concurrent Chemotherapy. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 552-556.	2.0	10
153	The Role of Survivin for Radiation Therapy. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 593-599.	2.0	74
154	Combined Systemic Therapy and Radiotherapy for Bladder Cancer. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 29-31.	2.0	5
155	Integration of Novel Agents into Combined-Modality Treatment for Rectal Cancer Patients. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 227-235.	2.0	87
156	Trimodality Treatment and Selective Organ Preservation for Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 5536-5544.	1.6	151
157	Combined Effect of Tumor Necrosis Factor-alpha and Ionizing Radiation on the Induction of Apoptosis in 5637 Bladder Carcinoma Cells. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 467-472.	2.0	18
158	Radiochemotherapy After Transurethral Resection for High-Risk T1 Bladder Cancer: An Alternative to Intravesical Therapy or Early Cystectomy?. <i>Journal of Clinical Oncology</i> , 2006, 24, 2318-2324.	1.6	105
159	Neoadjuvant Radiotherapy and Radiochemotherapy for Rectal Cancer. , 2005, 165, 221-230.		14
160	Organ preservation by combined modality treatment in bladder cancer: The European perspective. <i>Seminars in Radiation Oncology</i> , 2005, 15, 28-35.	2.2	36
161	Combined-Modality Treatment and Organ Preservation in Bladder Cancer. <i>Strahlentherapie Und Onkologie</i> , 2005, 181, 213-222.	2.0	24
162	Survivin as a Radioresistance Factor, and Prognostic and Therapeutic Target for Radiotherapy in Rectal Cancer. <i>Cancer Research</i> , 2005, 65, 4881-4887.	0.9	248

#	ARTICLE	IF	CITATIONS
163	What is the role of radiotherapy in bladder-preserving cancer therapy?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 4-5.	4.3	193
164	Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 8688-8696.	1.6	1,102
165	Neoadjuvant Radiochemotherapy in Rectal Cancer: For Which Patients and Tumor Stages?. , 2004, 38, 13-23.		2
166	Radiotherapy and concurrent radiochemotherapy for rectal cancer. <i>Surgical Oncology</i> , 2004, 13, 93-101.	1.6	16
167	Current Status of Radiation Therapy and Combined-Modality Treatment for Bladder Cancer. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 701-709.	2.0	27
168	Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 1731-1740.	27.0	5,296
169	Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: Survivin as a radioresistance factor. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 1341-1347.	0.8	146
170	Phase I/II Trial of Capecitabine, Oxaliplatin, and Radiation for Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 3098-3104.	1.6	277
171	P27 does not predict histopathological response to radiochemotherapy in rectal cancer. <i>Journal of Surgical Research</i> , 2003, 113, 179-188.	1.6	11
172	Combined-Modality Treatment and Selective Organ Preservation in Invasive Bladder Cancer: Long-Term Results. <i>Journal of Clinical Oncology</i> , 2002, 20, 3061-3071.	1.6	602
173	High Survivin Expression is Associated with Reduced Apoptosis in Rectal Cancer and May Predict Disease-Free Survival after Preoperative Radiochemotherapy and Surgical Resection. <i>Strahlentherapie Und Onkologie</i> , 2002, 178, 426-435.	2.0	94
174	Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 294-303.	0.8	119
175	Organ preservation in patients with invasive bladder cancer: initial results of an intensified protocol of transurethral surgery and radiation therapy plus concurrent cisplatin and 5-fluorouracil. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 1303-1309.	0.8	43
176	Radiotherapy is an Effective Treatment for High-Risk T1-Bladder Cancer. <i>Strahlentherapie Und Onkologie</i> , 2001, 177, 82-88.	2.0	23
177	Adjuvant versus Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer A Progress Report of a Phase-III Randomized Trial (Protocol CAO/ARO/AIO-94). <i>Strahlentherapie Und Onkologie</i> , 2001, 177, 173-181.	2.0	115
178	Perioperative radiotherapy and concurrent radiochemotherapy in rectal cancer. <i>Journal of Surgical Oncology</i> , 2001, 20, 3-12.	1.4	19
179	Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy. <i>Journal of Surgical Oncology</i> , 2001, 20, 24-32.	1.4	50
180	Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 46, 1213-1221.	0.8	104

#	ARTICLE	IF	CITATIONS
181	Preoperative Radiation with Concurrent 5-Fluorouracil for Locally Advanced T4-Primary Rectal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2000, 176, 161-167.	2.0	70